Publications

Export 8 results:
Author Title [ Type(Asc)] Year
Filters: Author is Foster, Jane A  [Clear All Filters]
Journal Article
Uher R, Frey BN, Quilty LC, Rotzinger S, Blier P, Foster JA, Müller DJ, Ravindran AV, Soares CN, Turecki G et al..  2020.  Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report.. J Clin Psychiatry. 81(4)
Phillips JL, Jaworska N, Kamler E, Bhat V, Blier J, Foster JA, Hassel S, Ho K, McMurray L, Milev R et al..  2020.  A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol.. BMC Psychiatry. 20(1):268.
Belzeaux R, Fiori LM, Lopez JPablo, Boucekine M, Boyer L, Blier P, Farzan F, Frey BN, Giacobbe P, Lam RW et al..  2019.  Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment.. J Clin Psychiatry. 80(3)
Ju C, Fiori LM, Belzeaux R, Théroux J-F, Chen GGang, Aouabed Z, Blier P, Farzan F, Frey BN, Giacobbe P et al..  2019.  Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants.. Transl Psychiatry. 9(1):254.
Belzeaux R, Gorgievski V, Fiori LM, Lopez JPablo, Grenier J, Lin R, Nagy C, Ibrahim EChérif, Gascon E, Courtet P et al..  2020.  GPR56/ADGRG1 is associated with response to antidepressant treatment.. Nat Commun. 11(1):1635.
Lam RW, Milev R, Rotzinger S, Andreazza AC, Blier P, Brenner C, Daskalakis ZJ, Dharsee M, Downar J, Evans KR et al..  2016.  Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.. BMC Psychiatry. 16:105.
Baskaran A, Farzan F, Milev R, Brenner CA, Alturi S, McAndrews MPat, Blier P, Evans K, Foster JA, Frey BN et al..  2017.  The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study.. J Affect Disord. 227:542-549.
Yrondi A, Fiori LM, Frey BN, Lam RW, Macqueen GM, Milev R, Müller DJ, Foster JA, Kennedy SH, Turecki G.  2019.  Association between side effects and blood microRNA expression levels and their targeted pathways in patients with major depressive disorder treated by a selective serotonin reuptake inhibitor, escitalopram: a CAN-BIND-1 report.. Int J Neuropsychopharmacol.